Related references
Note: Only part of the references are listed.Inborn errors of coenzyme A metabolism and neurodegeneration
Ivano Di Meo et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2019)
The FOsmetpantotenate Replacement Therapy (FORT) randomized, double-blind, Placebo-controlled pivotal trial: Study design and development methodology of a novel primary efficacy outcome in patients with pantothenate kinase-associated neurodegeneration
Thomas Klopstock et al.
CLINICAL TRIALS (2019)
Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study
Thomas Klopstock et al.
LANCET NEUROLOGY (2019)
Diagnostic and clinical experience of patients with pantothenate kinase-associated neurodegeneration
Randall D. Marshall et al.
ORPHANET JOURNAL OF RARE DISEASES (2019)
4′-Phosphopantetheine corrects CoA, iron, and dopamine metabolic defects in mammalian models of PKAN
Suh Young Jeong et al.
EMBO MOLECULAR MEDICINE (2019)
A Scale to Assess Activities of Daily Living in Pantothenate Kinase-Associated Neurodegeneration
Randall D. Marshall et al.
MOVEMENT DISORDERS CLINICAL PRACTICE (2019)
Fosmetpantotenate (RE-024), a phosphopantothenate replacement therapy for pantothenate kinase-associated neurodegeneration: Mechanism of action and efficacy in nonclinical models
Daniel Elbaum et al.
PLOS ONE (2018)
A therapeutic approach to pantothenate kinase associated neurodegeneration
Lalit Kumar Sharma et al.
NATURE COMMUNICATIONS (2018)
Consensus clinical management guideline for pantothenate kinase-associated neurodegeneration (PKAN)
Penelope Hogarth et al.
MOLECULAR GENETICS AND METABOLISM (2017)
Neurodegeneration with Brain Iron Accumulation: Genetic Diversity and Pathophysiological Mechanisms
Esther Meyer et al.
ANNUAL REVIEW OF GENOMICS AND HUMAN GENETICS, VOL 16 (2015)
Defective pantothenate metabolism and neurodegeneration
Susan J. Hayflick
BIOCHEMICAL SOCIETY TRANSACTIONS (2014)
Alteration of the coenzyme A biosynthetic pathway in neurodegeneration with brain iron accumulation syndromes
Paola Venco et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2014)
Iron-Related MRI Images in Patients with Pantothenate Kinase-Associated Neurodegeneration (PKAN) Treated with Deferiprone: Results of a Phase II Pilot Trial
Giovanna Zorzi et al.
MOVEMENT DISORDERS (2011)
Rating scales for dystonia in cerebral palsy: reliability and validity
E. Monbaliu et al.
DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY (2010)
Clinical and genetic delineation of neurodegeneration with brain iron accumulation
A. Gregory et al.
JOURNAL OF MEDICAL GENETICS (2009)
Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale Presentation and Clinimetric Testing Results
Christopher G. Goetz et al.
MOVEMENT DISORDERS (2008)
Genotypic and phenotypic spectrum of PANK2 mutations in patients with neurodegeneration with brain iron accumulation
MB Hartig et al.
ANNALS OF NEUROLOGY (2006)
Coenzyme A: Back in action
R Leonardi et al.
PROGRESS IN LIPID RESEARCH (2005)
Altered neuronal mitochondrial coenzyme a synthesis in neurodegeneration with brain iron accumulation caused by abnormal processing, stability, and catalytic activity of mutant pantothenate kinase 2
PT Kotzbauer et al.
JOURNAL OF NEUROSCIENCE (2005)
An isoform of hPANK2, deficient in pantothenate kinase-associated neurodegeneration, localizes to mitochondria
K Hörtnagel et al.
HUMAN MOLECULAR GENETICS (2003)
Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome.
SJ Hayflick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome
B Zhou et al.
NATURE GENETICS (2001)
Share Paper
